The propose of this review is to provide a new treatment for hypertriglyceridemia (HTG) subjects. Current innovative therapeutic options using monoclonal antibodies or gene silencing approaches to block ApolipoproteinC3 (APOC3) may minimize the risk of acute pancreatitis and atherosclerosis in HTG individuals. The review also discusses two drugs for HTG treatment, vupanorsen and olezarsen. The results of studies found that both can reduce Triglyceride (TG) levels very well. However, olezarsen, seems to have a better safety than vupanorsen, resulting in quality of life and illness from treatment of patients in this group improved.
No takes yet. Share an insight, caveat, or question.
Wanee Plengpanich (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: